CareCloud (NASDAQ:CCLD - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect CareCloud to post earnings of $0.22 per share and revenue of $27.99 million for the quarter. Parties interested in listening to the company's conference call can do so using this link.
CareCloud Trading Down 21.3 %
CCLD traded down $0.45 on Friday, reaching $1.66. The stock had a trading volume of 1,503,784 shares, compared to its average volume of 550,808. CareCloud has a fifty-two week low of $1.01 and a fifty-two week high of $4.84. The firm has a 50-day moving average of $3.46 and a 200-day moving average of $3.08. The company has a market capitalization of $26.98 million, a price-to-earnings ratio of -0.52 and a beta of 1.55.
Analysts Set New Price Targets
CCLD has been the subject of a number of recent research reports. Roth Capital cut CareCloud from a "strong-buy" rating to a "hold" rating in a report on Wednesday, November 13th. Benchmark reaffirmed a "buy" rating and issued a $4.50 target price on shares of CareCloud in a report on Friday, November 15th. Finally, Roth Mkm cut CareCloud from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $5.00 to $3.50 in a report on Wednesday, November 13th.
View Our Latest Stock Report on CCLD
CareCloud Company Profile
(
Get Free Report)
CareCloud, Inc, a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. It operates in two segments, Healthcare IT and Medical Practice Management. The company's portfolio of proprietary software and business services includes technology-enabled business solutions; cloud-based software; digital health services; healthcare IT professional services and staffing; and medical practice management services.
Read More
Before you consider CareCloud, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareCloud wasn't on the list.
While CareCloud currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
